Similar articles for PMID: 26782932

Year	Number of Results
1998	1
2002	1
2003	1
2004	3
2005	4
2006	6
2008	1
2009	1
2010	3
2011	3
2012	7
2013	7
2014	9
2015	14
2016	13
2017	7
2018	12
2019	13
2020	9
2021	6
2022	5
2023	3
2024	0

1

Co-treatment of wild-type EGFR head and neck cancer cell lines with afatinib and cisplatin.

Brands RC, Müller-Richter UD, De Donno F, Seher A, Mutzbauer G, Linz C, Kübler AC, Hartmann S. Brands RC, et al. Mol Med Rep. 2016 Mar;13(3):2338-44. doi: 10.3892/mmr.2016.4786. Epub 2016 Jan 14. Mol Med Rep. 2016. PMID: 26782932

2

Simultaneous targeting of EGFR, HER2, and HER4 by afatinib overcomes intrinsic and acquired cetuximab resistance in head and neck squamous cell carcinoma cell lines.

De Pauw I, Lardon F, Van den Bossche J, Baysal H, Fransen E, Deschoolmeester V, Pauwels P, Peeters M, Vermorken JB, Wouters A. De Pauw I, et al. Mol Oncol. 2018 Jun;12(6):830-854. doi: 10.1002/1878-0261.12197. Epub 2018 May 1. Mol Oncol. 2018. PMID: 29603584 Free PMC article.

3

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM. Huang S, et al. Cancer Res. 2004 Aug 1;64(15):5355-62. doi: 10.1158/0008-5472.CAN-04-0562. Cancer Res. 2004. PMID: 15289342

4

Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.

Nakamura Y, Togashi Y, Nakahara H, Tomida S, Banno E, Terashima M, Hayashi H, de Velasco MA, Sakai K, Fujita Y, Okegawa T, Nutahara K, Hamada S, Nishio K. Nakamura Y, et al. Mol Cancer Ther. 2016 Aug;15(8):1988-97. doi: 10.1158/1535-7163.MCT-15-0737. Epub 2016 May 20. Mol Cancer Ther. 2016. PMID: 27207775

5

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.

Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K. Erjala K, et al. Clin Cancer Res. 2006 Jul 1;12(13):4103-11. doi: 10.1158/1078-0432.CCR-05-2404. Clin Cancer Res. 2006. PMID: 16818711

6

Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.

Burtness B, Bourhis JP, Vermorken JB, Harrington KJ, Cohen EE. Burtness B, et al. Trials. 2014 Nov 29;15:469. doi: 10.1186/1745-6215-15-469. Trials. 2014. PMID: 25432788 Free PMC article. Clinical Trial.

7

Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo.

Young NR, Soneru C, Liu J, Grushko TA, Hardeman A, Olopade OI, Baum A, Solca F, Cohen EE. Young NR, et al. Target Oncol. 2015 Dec;10(4):501-8. doi: 10.1007/s11523-014-0353-6. Epub 2015 Jan 6. Target Oncol. 2015. PMID: 25559287 Free PMC article.

8

Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.

Michmerhuizen NL, Leonard E, Matovina C, Harris M, Herbst G, Kulkarni A, Zhai J, Jiang H, Carey TE, Brenner JC. Michmerhuizen NL, et al. Mol Pharmacol. 2019 May;95(5):528-536. doi: 10.1124/mol.118.115162. Epub 2019 Mar 11. Mol Pharmacol. 2019. PMID: 30858165 Free PMC article.

9

Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.

Macha MA, Rachagani S, Qazi AK, Jahan R, Gupta S, Patel A, Seshacharyulu P, Lin C, Li S, Wang S, Verma V, Kishida S, Kishida M, Nakamura N, Kibe T, Lydiatt WM, Smith RB, Ganti AK, Jones DT, Batra SK, Jain M. Macha MA, et al. Oncotarget. 2017 Mar 28;8(13):20961-20973. doi: 10.18632/oncotarget.15468. Oncotarget. 2017. PMID: 28423495 Free PMC article.

10

Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.

Bruzzese F, Di Gennaro E, Avallone A, Pepe S, Arra C, Caraglia M, Tagliaferri P, Budillon A. Bruzzese F, et al. Clin Cancer Res. 2006 Jan 15;12(2):617-25. doi: 10.1158/1078-0432.CCR-05-1671. Clin Cancer Res. 2006. PMID: 16428508

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

120 results

Results by year